It was another busy week for Australia's top brokers. This has led to the release of a number of broker notes.
Three broker buy ratings that you might want to know more about are summarised below. Here's why brokers think these ASX shares are in the buy zone:
Image source: Getty Images
Credit Corp Group Ltd (ASX: CCP)
According to a note out of Morgans, its analysts have retained their buy rating on this debt collector's shares with a reduced price target of $19.35. This follows the release of Credit Corp's first-half results, which revealed profits that were 10% short of expectations. While disappointing, Morgans feels the selloff that followed, which dragged its shares 17% lower, was overdone and has created a buying opportunity for investors. The broker highlights that at just 7x estimated FY 2027 earnings, Credit Corp's valuation is undemanding. This is especially the case given that management has reiterated its guidance for FY 2026. The Credit Corp share price ended the week at $11.25.
NextDC Ltd (ASX: NXT)
A note out of Macquarie reveals that its analysts have retained their outperform rating and $22.30 price target on this data centre operator's shares. Macquarie points out that Singtel and private equity firm KKR have acquired Singapore-based ST Telemedia Global Data Centres for approximately S$13.8 billion (A$15.5 billion). It estimates that this represents a 20x EV/EBITDA multiple, which is significantly greater than its 14.8x estimate for NextDC shares. In light of this, the broker continues to believe that NextDC shares are significantly undervalued at current levels, making now an opportune time for investors to open positions. The NextDC share price was fetching $12.71 at Friday's close.
ResMed Inc. (ASX: RMD)
Another note out of Morgans reveals that its analysts have upgraded this sleep disorder treatment company's shares to a buy rating with a $47.73 price target. Morgans was pleased with ResMed's performance in the second quarter of FY 2026. The broker highlights that its result was a beat across the board, with double-digit revenue and earnings growth, further gross margin expansion, and solid cash generation. In response to ResMed's operating leverage, the broker has lifted its earnings estimates and valuation slightly. And with its shares down materially from recent highs, Morgans thinks now is a good time to invest. The ResMed share price ended the week at $37.92.
